Janet M Raboud

Summary

Publications

  1. pmc Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
  2. doi request reprint Once daily dosing improves adherence to antiretroviral therapy
    Janet Raboud
    Division of Infectious Disease, University Health Network, Toronto, ON, Canada
    AIDS Behav 15:1397-409. 2011
  3. pmc A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy
    Janet M Raboud
    University of Toronto, Toronto, Canada
    HIV Clin Trials 11:39-50. 2010
  4. doi request reprint Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy
    Janet Raboud
    University Health Network, Toronto, Ontario, Canada
    HIV Clin Trials 11:340-50. 2010
  5. doi request reprint Association of vitamin D related information from a telephone interview with 25-hydroxyvitamin D
    Harleen Sahota
    Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 60 Murray Street, Toronto, Ontario, Canada
    Cancer Epidemiol Biomarkers Prev 17:232-8. 2008
  6. doi request reprint Four-year follow-up of polyalkylimide gel use for the treatment of HIV-associated lipoatrophy
    Mona R Loutfy
    Maple Leaf Medical Clinic, Toronto, Ontario, Canada
    HIV Clin Trials 12:323-32. 2011
  7. pmc Gender and ethnicity differences in HIV-related stigma experienced by people living with HIV in Ontario, Canada
    Mona R Loutfy
    Department of Medicine, Women s College Research Institute, Women s College Hospital, Toronto, Ontario, Canada
    PLoS ONE 7:e48168. 2012
  8. doi request reprint Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer
    Kristina M Blackmore
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 60 Murray Street, Box 18, Toronto, Ontario, Canada M5T3L9
    Am J Epidemiol 168:915-24. 2008
  9. doi request reprint Vitamin D association with estradiol and progesterone in young women
    Julia A Knight
    Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    Cancer Causes Control 21:479-83. 2010
  10. doi request reprint Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada
    Nisha Andany
    Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    HIV Clin Trials 12:89-103. 2011

Detail Information

Publications24

  1. pmc Regional differences in rates of HIV-1 viral load monitoring in Canada: Insights and implications for antiretroviral care in high income countries
    Janet M Raboud
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    BMC Infect Dis 10:40. 2010
    ....
  2. doi request reprint Once daily dosing improves adherence to antiretroviral therapy
    Janet Raboud
    Division of Infectious Disease, University Health Network, Toronto, ON, Canada
    AIDS Behav 15:1397-409. 2011
    ..Other independent correlates of suboptimal adherence were younger age, lower positive social interaction and increased frequency of consuming > 6 alcoholic drinks on one occasion...
  3. pmc A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy
    Janet M Raboud
    University of Toronto, Toronto, Canada
    HIV Clin Trials 11:39-50. 2010
    ..To determine the impact of thiazolidinediones (TZD) on changes in limb fat mass in HIV-infected individuals, particularly in those not receiving a thymidine analogue...
  4. doi request reprint Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy
    Janet Raboud
    University Health Network, Toronto, Ontario, Canada
    HIV Clin Trials 11:340-50. 2010
    ..To determine the effects of gender and calendar year on time to and duration of virologic suppression among HIV-infected antiretroviral-naïve individuals initiating combination antiretroviral therapy (cART)...
  5. doi request reprint Association of vitamin D related information from a telephone interview with 25-hydroxyvitamin D
    Harleen Sahota
    Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 60 Murray Street, Toronto, Ontario, Canada
    Cancer Epidemiol Biomarkers Prev 17:232-8. 2008
    ..82 versus "none"; P = 0.0006). The R(2) was 0.29 for the summer model and was 0.21 for the winter model. Overall, there was evidence to suggest that questions designed to assess vitamin D exposure were in fact related to serum 25(OH)D...
  6. doi request reprint Four-year follow-up of polyalkylimide gel use for the treatment of HIV-associated lipoatrophy
    Mona R Loutfy
    Maple Leaf Medical Clinic, Toronto, Ontario, Canada
    HIV Clin Trials 12:323-32. 2011
    ..To evaluate polyalkylamide gel (PAIG) use in treating HIV-associated facial lipoatrophy (FLA) 4 years after its injection in an open-label, randomized controlled trial (RCT)...
  7. pmc Gender and ethnicity differences in HIV-related stigma experienced by people living with HIV in Ontario, Canada
    Mona R Loutfy
    Department of Medicine, Women s College Research Institute, Women s College Hospital, Toronto, Ontario, Canada
    PLoS ONE 7:e48168. 2012
    ..Findings suggest differing approaches may be required to address HIV-related stigma based on gender and ethnicity; and such strategies should challenge racist and sexist stereotypes...
  8. doi request reprint Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer
    Kristina M Blackmore
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 60 Murray Street, Box 18, Toronto, Ontario, Canada M5T3L9
    Am J Epidemiol 168:915-24. 2008
    ..51, 1.22) tumors. This study suggests that vitamin D is associated with a reduced risk of breast cancer regardless of ER/PR status of the tumor. Future studies with a larger number of receptor-negative and mixed tumors are required...
  9. doi request reprint Vitamin D association with estradiol and progesterone in young women
    Julia A Knight
    Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
    Cancer Causes Control 21:479-83. 2010
    ..We conducted a study to determine whether there is an association between circulating 25-hydroxyvitamin D (25(OH)D) and estradiol and progesterone in young women...
  10. doi request reprint Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada
    Nisha Andany
    Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    HIV Clin Trials 12:89-103. 2011
    ..This study assessed ethnicity and gender differences in prevalence, type, and severity of antiretroviral-associated lipodystrophy in HIV-positive individuals in Ontario...
  11. doi request reprint Herpes simplex virus type 2 coinfection does not accelerate CD4 count decline in untreated HIV infection
    Darrell H S Tan
    St Michael s Hospital, Division of Infectious Diseases, 30 Bond St, 4CC Rm 4 179, Toronto, ON M5B 1W8, Canada
    Clin Infect Dis 57:448-57. 2013
    ..We compared rates of CD4 count decline according to HSV-2 status in untreated HIV-infected adults...
  12. doi request reprint Immunologic effectiveness of maraviroc- and raltegravir-containing regimens (R+M+) versus raltegravir-based regimens that do not include maraviroc (R+M-)
    Tony Antoniou
    1University of Toronto, Toronto, Ontario, Canada
    J Int Assoc Physicians AIDS Care (Chic) 11:192-7. 2012
    ..To compare the immunologic effectiveness of raltegravir-maraviroc (R+M+)-based regimens with raltegravir-based regimens that do not include maraviroc (R+M-) in treatment-experienced patients in clinical practice...
  13. doi request reprint Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy
    Leah Szadkowski
    Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    AIDS Res Hum Retroviruses 28:1579-83. 2012
    ..Further studies should investigate adherence, comorbidities, and regimen changes in addition to the current covariates...
  14. pmc Fertility desires and intentions of HIV-positive women of reproductive age in Ontario, Canada: a cross-sectional study
    Mona R Loutfy
    Women s College Research Institute, Women s College Hospital, Toronto, Ontario, Canada
    PLoS ONE 4:e7925. 2009
    ..In order to clarify the demand, and aid with appropriate health services planning for this population, our study aims to assess the fertility desires and intentions of HIV-positive women of reproductive age living in Ontario, Canada...
  15. doi request reprint Persistent HIV RNA shedding in semen despite effective antiretroviral therapy
    Prameet M Sheth
    Department of Medicine, Dalla Lana School of Public Health, Toronto, Ontario, Canada
    AIDS 23:2050-4. 2009
    ..Isolates were drug-sensitive, and this phenomenon was not associated with semen drug levels or regimen...
  16. doi request reprint Significant differences in clinical outcomes between HIV-hepatitis C virus coinfected individuals with and without injection drug use history
    Angela Cescon
    aBritish Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia bUniversity Health Network, Toronto cUniversity of Toronto dOntario HIV Treatment Network, Toronto, Ontario eMcGill University, Montreal, Quebec fWomen s College Research Institute, Toronto gMaple Leaf Medical Clinic, Toronto, Ontario hClinique Médicale l Actuel, Montreal, Quebec iUniversity of British Columbia, Vancouver jSimon Fraser University, Burnaby, British Columbia kUniversity of Ottawa, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada The members of the CANOC Collaboration are listed in the Acknowledgements
    AIDS 28:121-7. 2014
    ..This study compares HIV treatment outcomes and survival between HIV-HCV coinfected individuals with and without IDU history...
  17. doi request reprint No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults
    Darrell Hs Tan
    University Health Network Division of Infectious Diseases, Canada bUniversity of Toronto, Ontario, Canada
    AIDS 25:207-10. 2011
    ..to determine the impact of oral tenofovir as part of combination antiretroviral therapy on asymptomatic herpes simplex virus (HSV) shedding...
  18. ncbi request reprint Nonfinancial factors associated with decreased plasma viral load testing in Ontario, Canada
    Janet M Raboud
    Division of Infectious Diseases, University Health Network, University of Toronto, Ontario, Canada
    J Acquir Immune Defic Syndr 39:327-32. 2005
    ..To examine whether individual characteristics were associated with differential use of viral load testing when testing is available without charge to all HIV-positive patients with provincial health insurance...
  19. pmc Desires, Need, Perceptions, and Knowledge of Assisted Reproductive Technologies of HIV-Positive Women of Reproductive Age in Ontario, Canada
    Yimeng Zhang
    Women and HIV Research Program, Women s College Research Institute, Women s College Hospital, Toronto, ON, Canada M5G 1N6
    ISRN Obstet Gynecol 2012:853503. 2012
    ..Fertility service professionals need to be aware of the increasing demand for ART among WLWHIV...
  20. pmc Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial
    Darrell H S Tan
    University Health Network, 585 University Ave, 13N 1323, Toronto, Ontario, M5G 2N2 Canada
    Trials 11:113. 2010
    ..Suppression of herpes simplex virus type 2 (HSV-2) may be a novel strategy for achieving this goal because HSV-2 is associated with clinically significant increases in HIV viral load, the primary driver of HIV disease progression...
  21. ncbi request reprint Light and exercise and melatonin production in women
    Julia A Knight
    Prosserman Centre for Health Research, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
    Am J Epidemiol 162:1114-22. 2005
    ..It is possible that the protective effect of exercise with respect to breast cancer may operate in part through an effect on melatonin...
  22. ncbi request reprint Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients
    Mona R Loutfy
    Maple Leaf Medical Clinic, 70 Carlton Street, Toronto, Ontario, Canada
    AIDS 21:1147-55. 2007
    ..To evaluate the safety and efficacy of polyalkylimide gel (PAIG) in the treatment of HIV-associated facial lipoatrophy...
  23. ncbi request reprint Vitamin D and reduced risk of breast cancer: a population-based case-control study
    Julia A Knight
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, 60 Murray Street, Box 18, Toronto, Ontario, Canada M5T 3L9
    Cancer Epidemiol Biomarkers Prev 16:422-9. 2007
    ..We conducted a population-based case-control study to assess the evidence for a relationship between sources of vitamin D and breast cancer risk...
  24. ncbi request reprint Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients
    Janet M Raboud
    Department of Public Health Sciences and Division of Infectious Diseases, University Health Network, University of Toronto, Toronto, Ontario, Canada
    AIDS 16:1627-32. 2002
    ..To describe the characteristics and predictors of transient plasma viral load (pVL) rebounds among patients on stable antiretroviral therapy and to determine the effect of one or more pVL rebounds on virological response at week 52...